ARCHIVES

Ibrutinib Produces 68% Overall Response Rate in Phase II Trial

This article is from The Cancer Letter archive.

Vol. 36 No. 1 | January 25, 2013

Download PDF Visit The Full Archive

Related Articles

Arbuck Leaves NCI to Guide BMS Oncology Pipeline.

September 7, 2001

Anti-Impoundment, Panel Stay In Cancer Renewal Act; Conferees Finally Agree On Research Training Bill

June 14, 1974

Some Children With Hodgkin’s Disease Can Reduce Or Skip Radiation, Study Finds

October 29, 2004

Chronobiology Review Still Delayed

May 5, 1989

In Brief: Senate Committee Confirms Varmus; Albertini Directs Vermont Cancer Center

November 19, 1993

Study Seeks Sisters Of Women With Breast Cancer

September 27, 2002